One widely studied and established approach combines cabotegravir and rilpivirine, administered through intramuscular injections. This treatment is available for eligible adults and adolescents who meet specific clinical requirements. Depending on the prescribed schedule, injections are generally administered monthly or every two months.
These treatments work by targeting different stages of the HIV life cycle. Cabotegravir belongs to the integrase strand transfer inhibitor class, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they help prevent HIV from multiplying.
Important considerations when evaluating long acting HIV therapy include:
Treatment eligibility: Patients generally need to have achieved sustained viral suppression on an appropriate antiretroviral regimen before switching to injectable treatment.
Medication schedules: Injections must be administered according to the recommended schedule to maintain effective drug concentrations.
Resistance considerations: Healthcare professionals assess previous treatment history and possible drug resistance before recommending injectable therapy.
Side effects: Injection site reactions, discomfort, headaches, and other adverse effects may occur.
Treatment continuity: Missing scheduled injections can increase the risk of reduced medication effectiveness and viral rebound.
Long acting HIV treatment is not suitable for everyone. Individual medical history, current viral load, medication interactions, and treatment preferences influence clinical decisions.
Regular health monitoring remains essential for people receiving long acting HIV therapy. Although these medications reduce the frequency of administration, they do not eliminate the need for medical appointments, laboratory testing, and ongoing assessment.
Viral load testing is one of the primary methods used to evaluate treatment effectiveness. It measures the amount of HIV RNA present in the blood. Maintaining an undetectable viral load indicates that treatment is successfully suppressing viral replication.
CD4 cell counts are another important monitoring measure. These tests help healthcare professionals understand immune system health and evaluate changes over time. Additional assessments may include liver and kidney function tests, screening for other infections, and evaluations of possible medication side effects.
Key components of ongoing monitoring include:
HIV viral load testing: Evaluates whether the medication combination continues to suppress HIV.
CD4 cell monitoring: Helps assess immune system function and recovery.
Safety assessments: Identifies potential adverse reactions and medication-related complications.
Injection appointment tracking: Supports timely administration and reduces the possibility of missed doses.
Resistance testing: May be recommended when treatment failure or viral rebound is suspected.
General health evaluations: Include screening for other infections, vaccination needs, and age appropriate preventive healthcare.
Healthcare professionals also discuss treatment adherence, injection site reactions, and changes in general health during follow up appointments.
If a scheduled injection is delayed, patients should contact their healthcare provider promptly because additional oral medication or an adjusted treatment schedule may be necessary. Consistent monitoring helps identify concerns early and supports informed decisions about continuing or changing HIV treatment.